PMID- 28477418
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 9
DP  - 2017 Sep
TI  - Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in 
      the kidney of type 2 diabetic subjects.
PG  - 1322-1326
LID - 10.1111/dom.13003 [doi]
AB  - The sodium-glucose co-transporters (SGLTs) are responsible for the tubular 
      reabsorption of filtered glucose from the kidney into the bloodstream. The 
      inhibition of SGLT2-mediated glucose reabsorption is a novel and highly effective 
      strategy to alleviate hyperglycaemia in patients with type 2 diabetes mellitus 
      (T2DM). However, the effectiveness of SGLT2 inhibitor therapy is diminished due, 
      in part, to a compensatory increase in the maximum reabsorptive capacity (Tm) for 
      glucose in patients with T2DM. We hypothesized that this increase in Tm could be 
      explained by an increase in the tubular expression of SGLT and glucose 
      transporters (GLUT) in these patients. To examine this, we obtained human kidney 
      biopsy specimens from patients with or without T2DM and examined the mRNA 
      expression of SGLTs and GLUTs. The expression of SGLT1 is markedly increased in 
      the kidney of patients with T2DM, and SGLT1 mRNA is highly and significantly 
      correlated with fasting and postprandial plasma glucose and HbA1c. In contrast, 
      our data demonstrate that the levels of SGLT2 and GLUT2 mRNA are downregulated in 
      diabetic patients, but not to a statistically significant level. These important 
      findings are clinically significant and may have implications for the treatment 
      of T2DM using strategies that target SGLT transporters in the kidney.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Norton, Luke
AU  - Norton L
AUID- ORCID: 0000-0002-0231-5722
AD  - Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.
FAU - Shannon, Christopher E
AU  - Shannon CE
AD  - Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.
FAU - Fourcaudot, Marcel
AU  - Fourcaudot M
AD  - Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.
FAU - Hu, Cheng
AU  - Hu C
AD  - Shanghai Diabetes Institute, Shanghai Jiaotong University School of Medicine, 
      Shanghai, China.
FAU - Wang, Niansong
AU  - Wang N
AD  - Shanghai Diabetes Institute, Shanghai Jiaotong University School of Medicine, 
      Shanghai, China.
FAU - Ren, Wei
AU  - Ren W
AD  - Shanghai Diabetes Institute, Shanghai Jiaotong University School of Medicine, 
      Shanghai, China.
FAU - Song, Jun
AU  - Song J
AD  - Shanghai Diabetes Institute, Shanghai Jiaotong University School of Medicine, 
      Shanghai, China.
FAU - Abdul-Ghani, Muhammad
AU  - Abdul-Ghani M
AUID- ORCID: 0000-0003-4556-1787
AD  - Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.
FAU - DeFronzo, Ralph A
AU  - DeFronzo RA
AD  - Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.
FAU - Ren, Jimmy
AU  - Ren J
AD  - Janssen Pharmaceuticals Inc, Raritan, New Jersey.
FAU - Jia, Weiping
AU  - Jia W
AD  - Shanghai Diabetes Institute, Shanghai Jiaotong University School of Medicine, 
      Shanghai, China.
LA  - eng
GR  - K01 DK098314/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170713
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Glucose Transporter Type 2)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (SLC2A1 protein, human)
RN  - 0 (SLC2A2 protein, human)
RN  - 0 (SLC5A1 protein, human)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 1)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Biopsy
MH  - Blood Glucose/analysis
MH  - China
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/*metabolism/pathology
MH  - Fasting
MH  - Female
MH  - *Gene Expression Regulation/drug effects
MH  - Glucose Transporter Type 1/genetics/metabolism
MH  - Glucose Transporter Type 2/genetics/*metabolism
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Kidney/drug effects/*metabolism/pathology
MH  - Male
MH  - Postprandial Period
MH  - RNA, Messenger/*metabolism
MH  - Reproducibility of Results
MH  - Sodium-Glucose Transporter 1/genetics/*metabolism
MH  - Sodium-Glucose Transporter 2/genetics/*metabolism
OTO - NOTNLM
OT  - glucose transporters (GLUT)
OT  - kidney
OT  - sodium-glucose co-transporters (SGLT)
OT  - type 2 diabetes
EDAT- 2017/05/10 06:00
MHDA- 2018/05/08 06:00
CRDT- 2017/05/07 06:00
PHST- 2017/02/09 00:00 [received]
PHST- 2017/04/18 00:00 [revised]
PHST- 2017/04/30 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
PHST- 2017/05/07 06:00 [entrez]
AID - 10.1111/dom.13003 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Sep;19(9):1322-1326. doi: 10.1111/dom.13003. Epub 2017 
      Jul 13.